GLP Watchdog

Best TRT Clinics in 2026 — Ranked & Reviewed

For clinically diagnosed hypogonadism, testosterone replacement therapy is legitimate treatment. It is also among the most aggressively marketed categories in all of men's telehealth, and the line between genuine symptom relief and overprescribing blurs easily. Four things decide the ranking below. Diagnostic rigor: symptoms plus two separate morning readings under 300 ng/dL, as the Endocrine Society's 2018 guideline requires, rather than a single test or a questionnaire. Ongoing lab monitoring: PSA and hematocrit drawn at baseline, then again at 3, 6 and 12 months. Formulary breadth: injectable, gel, or fertility-preserving options such as enclomiphene. And pricing you can read. A clinic that prescribes testosterone off a symptom checklist alone is not ranked here at all.

Lowest verified price: $100/mo1 provider compared

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed (not clinically reviewed). Not medical advice · How we verify contentLast reviewed

1 trt clinics compared · independently scored against our six-factor methodology.

Quick Picks: Top 1

#ProviderScore
1BrightmedsVisit
6weighted dimensions
1trt clinics compared
Everychecked against the seller's own site
Value 25%Effectiveness 25%User Experience 15%Trust & Safety 15%Accessibility 10%Support 10%

A seller that shows no price until after the medical intake loses points on User Experience and Trust & Safety, and its review says so. How we score →

Detailed Reviews

1

Brightmeds

Best for: knowing which pharmacy fills the vial: it names Beaker Pharmacy

8.4

Compounded semaglutide opens at $189/mo, with tirzepatide at $289/mo, priced flat whatever the dose, but what renewal costs later is not published until the intake quiz is done. A single membership spans longevity peptides (sermorelin, NAD+, glutathione), TRT aimed at men, and GLP-1 weight loss. Both modalities are stocked, compounded drugs with microdosing protocols included and branded Zepbound in pens and vials, a mix rarely seen. 47 states are served.

Score Breakdown

Value25%
10
Effectiveness25%
10
User Experience15%
3
Trust & Safety15%
7.5
Accessibility10%
9.5
Support10%
8.5

Pros

  • ✓Semaglutide costs $189 a month, close to the $185 median for compounded semaglutide across the sellers we compare
  • ✓Tirzepatide costs $100 a month, 60% below the $250 median for compounded tirzepatide across the sellers we compare
  • ✓The monthly price stays the same as your dose goes up
  • ✓The monthly price includes the medication, clinician visits, shipping and lab work
  • ✓Serves 47 states
  • ✓Names 2 pharmacies that fill its prescriptions, which most sellers do not
  • ✓We found no FDA warning letters issued to Brightmeds

Cons

  • ✗You only see a price after finishing the medical intake, so you cannot compare costs before sharing health information
  • ✗Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Starting from $100/moRead full review →
Visit Brightmeds →

What a TRT clinic has to do before prescribing

Testosterone replacement is real medical therapy, and a diagnostic threshold comes attached to it. That threshold is the dividing line on this page. Some clinics test against it before writing anything and keep testing afterward. Others treat it as paperwork.

What to check

  • Two morning draws, not a symptom quiz. Hypogonadism under the Endocrine Society standard needs two separate morning total-testosterone results below 300 ng/dL, together with symptoms that fit. A single draw, an afternoon draw, or a checklist standing in for a lab each puts the prescription outside that guideline.
  • Labs after the first prescription. Baseline, three months, six months, then yearly is the cadence for hematocrit and PSA. Above 50% hematocrit, the dose comes down. A clinic drawing blood once at the start has dropped the part of the therapy that prevents harm.
  • Formulary, and what it does to fertility. Cypionate by injection is the cheapest and most widely used form. Gel removes the needle and adds a transfer risk to anyone in close contact. Enclomiphene lifts endogenous testosterone and leaves fertility intact. Anyone planning children needs that conversation before a first dose, not after it.

Red flags

  • A script written off a questionnaire. Two morning draws below 300 ng/dL, with matching symptoms, are what make a low-testosterone diagnosis defensible. Skipping the confirmatory second test is the pellet-mill pattern. It is not a workup that fell slightly short.
  • Hematocrit and PSA checked once, or never. Red blood cell mass rises on testosterone, and an undiagnosed prostate condition can move faster under it. Rechecks at three, six and twelve months are how either gets caught. A clinic running none of them is refilling a prescription, which is a different job from managing a therapy.
  • Pellets offered to a first-time patient. Once a pellet is implanted, its dose cannot be lowered. If hematocrit or PSA climbs, the remaining choices are waiting it out or surgery to take it back out. That is a poor position to be in before anyone knows how a patient responds to testosterone.
  • Nobody named, no cadence published. Who writes the prescription, and how often the labs repeat, are two facts a clinic can publish. Where a site publishes neither, and the therapy carries genuine cardiovascular and hematologic monitoring requirements, that absence is disqualifying on its own.

Every seller listed above is scored on these criteria under our six-dimension methodology, with prices re-checked against the seller’s own live site.

How we rank, and what counts as “legit”

Scoring for every provider on this page runs against our published six-factor rubric[1]: value, effectiveness, user experience, trust & safety, accessibility and support.

Each of Wegovy, Zepbound, Ozempic and Mounjaro holds its own separate FDA approval under its own NDA number[4][5]. Published Phase 3 efficacy for semaglutide at 2.4 mg (~14.9% mean weight loss across 68 weeks) comes from STEP 1[6]; those for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) come from SURMOUNT-1[7]. In 2025 the SURMOUNT-5 head-to-head set the two against each other[8].

How much of an anti-obesity medication is covered varies widely between state Medicaid programs and between commercial plans[9][10]. Under IRS Publication 502, compounded GLP-1s and brand-name ones alike are generally FSA/HSA eligible where a prescription exists[11].

Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

Frequently Asked Questions

Hypogonadism, under the 2018 Endocrine Society clinical practice guideline, means consistent symptoms together with total testosterone below 300 ng/dL, measured on at least two separate mornings on different days. Morning timing matters: total testosterone peaks between 7-10 AM, then drops 20-25% by afternoon. A complete workup adds SHBG, free testosterone, FSH, LH, prolactin and PSA, plus a CBC to establish baseline hematocrit.
TRAVERSE, the landmark trial on cardiovascular safety (NEJM 2023, n=5,246; hypogonadal men aged 45-80 who had cardiovascular disease or risk of it), found testosterone gel non-inferior to placebo on major adverse cardiac events across 22 months of follow-up. In the TRT arm it also flagged higher rates of pulmonary embolism, acute kidney injury and atrial fibrillation, which is why a prior unprovoked blood clot or arrhythmia warrants added caution.
Cash-pay only is the norm for direct-to-consumer TRT telehealth. Commercial insurance and Medicare will cover TRT where hypogonadism is documented properly, meaning symptoms, low total testosterone on two morning draws, and appropriate diagnosis coding, and that route usually runs through an endocrinologist, urologist or primary-care doctor, dispensed at a retail pharmacy. Where a covered prescriber is already in place, that route generally costs less than paying cash direct to consumer.
Six weighted dimensions produce the score. Value (25%) and Effectiveness (25%) carry the most, then User Experience (15%) and Trust & Safety (15%), then Accessibility (10%) and Support (10%). Behind them sits our research into pricing data, clinical evidence, user reviews and publicly available information. Those weights then combine into one overall score out of 10.
The six-dimension methodology computes each score on its own, and no commercial relationship ever moves a provider's underlying number. Every provider's full score sits on its card for you to check. Some providers do hold affiliate agreements with us, which means a commission reaches us if you click through and buy. On the lists carrying the highest commercial intent — the weight-loss injection and shot lists, the semaglutide and tirzepatide lists, the compounded and cheapest molecule lists, and the fitness-app list, plus the rankings we run for ED telehealth, TRT clinics and HRT providers — affiliate partners take the top positions. Every other list runs in score order, or in price order on the cheapest lists. That placement is disclosed here, on our methodology page, and on our affiliate-disclosure page.
Sources & methodology — as of September 2026
  1. 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
  2. 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  3. 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  4. 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  5. 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  6. 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
  7. 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
  8. 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
  9. 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
  10. 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
  11. 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Related Rankings